Cargando…

Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer

Although normally restricted to activated T and B cells and mature dendritic cells, constitutive expression of CD70, a member of the tumor necrosis family, has been described in both hematological and solid tumors, where it increases tumor cell and regulatory T cell survival by signaling through its...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jacobs, Julie, Zwaenepoel, Karen, Rolfo, Christian, Van den Bossche, Jolien, Deben, Christophe, Silence, Karen, Hermans, Christophe, Smits, Evelien, Van Schil, Paul, Lardon, Filip, Deschoolmeester, Vanessa, Pauwels, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4537027/ https://www.ncbi.nlm.nih.gov/pubmed/25951351

Ejemplares similares

Preclinical data on the combination of cisplatin and anti-CD70 therapy in non-small cell lung cancer as an excellent match in the era of combination therapy
por: Jacobs, Julie, et al.
Publicado: (2017)

Hypoxia-Induced Cisplatin Resistance in Non-Small Cell Lung Cancer Cells Is Mediated by HIF-1α and Mutant p53 and Can Be Overcome by Induction of Oxidative Stress
por: Deben, Christophe, et al.
Publicado: (2018)

The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer
por: Deben, Christophe, et al.
Publicado: (2015)

Towards Prognostic Profiling of Non-Small Cell Lung Cancer: New Perspectives on the Relevance of Polo-Like Kinase 1 Expression, the TP53 Mutation Status and Hypoxia
por: Van den Bossche, Jolien, et al.
Publicado: (2017)

MDM2 SNP309 and SNP285 Act as Negative Prognostic Markers for Non-small Cell Lung Cancer Adenocarcinoma Patients
por: Deben, Christophe, et al.
Publicado: (2017)

In vitro study of the Polo‐like kinase 1 inhibitor volasertib in non‐small‐cell lung cancer reveals a role for the tumor suppressor p53
por: Van den Bossche, Jolien, et al.
Publicado: (2019)

Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect
por: Jacobs, Julie, et al.
Publicado: (2015)

Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer
por: Van Der Steen, Nele, et al.
Publicado: (2016)

Targeting CD70 in combination with chemotherapy to enhance the anti-tumor immune effects in non-small cell lung cancer
por: Flieswasser, Tal, et al.
Publicado: (2023)

The Role of c-Met as a Biomarker and Player in Innate and Acquired Resistance in Non-Small-Cell Lung Cancer: Two New Mutations Warrant Further Studies
por: Van Der Steen, Nele, et al.
Publicado: (2019)

Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines
por: De Pauw, Ines, et al.
Publicado: (2018)

Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status
por: Van den Bossche, Jolien, et al.
Publicado: (2019)

The CD70-CD27 axis in oncology: the new kids on the block
por: Flieswasser, Tal, et al.
Publicado: (2022)

Mass Spectrometry Imaging Reveals Neutrophil Defensins as Additional Biomarkers for Anti-PD-(L)1 Immunotherapy Response in NSCLC Patients
por: Berghmans, Eline, et al.
Publicado: (2020)

OrBITS: label-free and time-lapse monitoring of patient derived organoids for advanced drug screening
por: Deben, Christophe, et al.
Publicado: (2022)

Expression of SARS-CoV-2-Related Surface Proteins in Non-Small-Cell Lung Cancer Patients and the Influence of Standard of Care Therapy
por: Deben, Christophe, et al.
Publicado: (2022)

Screening a Broad Range of Solid and Haematological Tumour Types for CD70 Expression Using a Uniform IHC Methodology as Potential Patient Stratification Method
por: Flieswasser, Tal, et al.
Publicado: (2019)

Auranofin Synergizes with the PARP Inhibitor Olaparib to Induce ROS-Mediated Cell Death in Mutant p53 Cancers
por: Freire Boullosa, Laurie, et al.
Publicado: (2023)

Circulating Cell-Free DNA and RNA Analysis as Liquid Biopsy: Optimal Centrifugation Protocol
por: Sorber, Laure, et al.
Publicado: (2019)

Auranofin and Cold Atmospheric Plasma Synergize to Trigger Distinct Cell Death Mechanisms and Immunogenic Responses in Glioblastoma
por: Van Loenhout, Jinthe, et al.
Publicado: (2021)

Optimization of the Solvent and In Vivo Administration Route of Auranofin in a Syngeneic Non-Small Cell Lung Cancer and Glioblastoma Mouse Model
por: Freire Boullosa, Laurie, et al.
Publicado: (2022)

A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy
por: De Waele, Jorrit, et al.
Publicado: (2021)

Immune Checkpoint Inhibitory Therapy in Sarcomas: Is There Light at the End of the Tunnel?
por: Siozopoulou, Vasiliki, et al.
Publicado: (2021)

Characterization of acquired nutlin-3 resistant non-small cell lung cancer cells
por: Deben, Christophe, et al.
Publicado: (2021)

The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies
por: Baysal, Hasan, et al.
Publicado: (2021)

Prognostic implications of cellular senescence in resected non-small cell lung cancer
por: Domen, Andreas, et al.
Publicado: (2022)

Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib
por: De Pauw, Ines, et al.
Publicado: (2019)

Oxidative Stress-Inducing Anticancer Therapies: Taking a Closer Look at Their Immunomodulating Effects
por: Van Loenhout, Jinthe, et al.
Publicado: (2020)

UAS™—A Urine Preservative for Oncology Applications
por: Jordaens, Stephanie, et al.
Publicado: (2023)

Evaluation of Cytologic Sample Preparations for Compatibility With Nucleic Acid Analysis
por: Sorber, Laure, et al.
Publicado: (2021)

Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer
por: Domen, Andreas, et al.
Publicado: (2021)

Cold Atmospheric Plasma-Treated PBS Eliminates Immunosuppressive Pancreatic Stellate Cells and Induces Immunogenic Cell Death of Pancreatic Cancer Cells
por: Van Loenhout, Jinthe, et al.
Publicado: (2019)

The prognostic impact of the immune signature in head and neck squamous cell carcinoma
por: Baysal, Hasan, et al.
Publicado: (2022)

Clinically Relevant Chemotherapeutics Have the Ability to Induce Immunogenic Cell Death in Non-Small Cell Lung Cancer
por: Flieswasser, Tal, et al.
Publicado: (2020)

Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients
por: Deschoolmeester, Vanessa, et al.
Publicado: (2010)

Cellular senescence in cancer: clinical detection and prognostic implications
por: Domen, Andreas, et al.
Publicado: (2022)

The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines
por: Boeckx, Carolien, et al.
Publicado: (2015)

Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status
por: Baysal, Hasan, et al.
Publicado: (2020)

The radiosensitising effect of gemcitabine and its main metabolite dFdU under low oxygen conditions is in vitro not dependent on functional HIF-1 protein
por: Wouters, An, et al.
Publicado: (2014)

Detection of HPV and the role of p16(INK4A )overexpression as a surrogate marker for the presence of functional HPV oncoprotein E7 in colorectal cancer
por: Deschoolmeester, Vanessa, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_ve223oe6oo8e6blgiquqmljfgi